FDA Priority Review of Lexicon’s New Drug Application for Telotristat Etiprate Treatment for Carcinoid Syndrome

Lexicon Pharmaceuticals announced on May 31, 2016 that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for the treatment of CARCINOID SYNDROME. “The FDA has granted a Priority Review of the NDA filing and set a Prescription Drug User Fee Act (“PDUFA”) target action date of November 30, 2016.” Read more

Print Friendly, PDF & Email